Rheumatology

The Rheumatology Revenue Reality

Rheumatology is medication-intensive, documentation-sensitive, and highly vulnerable to authorization and drug-billing friction. Revenue leakage is rarely caused by one dramatic event. It usually builds through repeated issues such as biologic prior authorization delays, incorrect J-code unit reporting, infusion administration errors, and missed JW/JZ modifier requirements.

• J-code unit and dose reporting errors for biologics
• Infusion administration and timing inaccuracies
• Prior authorization expirations and step-therapy delays
• JA/JB modifier omissions for route-specific billing
• JW/JZ modifier mistakes for discarded drug reporting
• Diagnosis-to-drug medical necessity mismatch
• Biosimilar reimbursement inconsistency across payers
• High-dollar AR concentration in denied infusion claims

Biologic, J-Code & Infusion Precision (CCP)

• J-code unit-to-dose validation
• Infusion administration coding integrity checks
• Route-of-administration modifier governance
• JW/JZ discarded-drug billing review
• Diagnosis, drug, and documentation alignment
• Buy-and-bill claim accuracy controls

Target Outcome: Reduced biologic billing errors and fewer high-value denials.

Front-End Eligibility, Authorization & Coverage Controls (FIO + EAE)

• Real-time eligibility verification
• Prior authorization tracking and renewal controls
• Step-therapy and payer-policy validation
• Site-of-care restriction review
• Benefit and specialty-drug coverage confirmation
• Referral and ordering-documentation verification

Target Outcome: Fewer authorization-related denials and cleaner claims.

High-Dollar AR Recovery & Denial Resolution (AAF)

• Structured follow-up on aged infusion balances
• Payer-specific appeal workflows for medical necessity
• Underpayment review on drug reimbursement lines
• AR > 90 monitoring by payer and drug class
• Follow-up prioritization for high-value denied claims

Target Outcome: Faster recovery of delayed reimbursements and improved turnover.

Drug Reimbursement & Denial Pattern Intelligence (PRL)

• Biologic denial trends by payer and policy type
• Drug reimbursement variance monitoring
• Biosimilar substitution pattern analysis
• Authorization failure clustering
• High-value AR aging concentration by payer mix

Target Outcome: Clear visibility into recurring rheumatology revenue leakage.

Measurable Performance Targets

• 8–18% increase in net collections
• 15–30% reduction in denial rates
• 25–40% reduction in AR > 90
• 95–98% first-pass claim acceptance
• Improved reimbursement consistency for biologics and infusions

Compliance & Infrastructure

• HIPAA-compliant workflows with BAA signed prior to PHI exchange
• Integration with major EHR platforms including Epic, Cerner, Athenahealth, NextGen, eClinicalWorks and others
• Cybersecurity oversight via Redfort Technologies
• U.S.-based nationwide operations